In vivo (skin DTH testing) and in vitro immune response analysis
| Test performed . | Pretransplant . | Posttransplant treatment . | Follow-up . | Any time point . | ||||
|---|---|---|---|---|---|---|---|---|
| Baseline . | Day 14 . | 1 . | 4 . | 8 . | 9 mo . | Off study . | ||
| Skin DTH testing | ||||||||
| Immunotherapy positive reaction* | 26/27 (96%) | 19/19 (100%) | 18/19 (95%) | 15/16 (94%) | 27/27 (100%) | |||
| Candida positive reaction* | 6/27 (22%) | 4/23 (17%) | 7/20 (35%) | 8/17 (47%) | 6/17 (35%) | 5/10 (50%) | 6/16 (38%) | 15/28 (54%) |
| Mumps positive reaction* | 4/8 (50%) | 3/6 (50%) | 1/3 (33%) | 1/2 (50%) | 1/1 (100%) | 4/8 (50%) | ||
| Tetanus positive reaction* | 2/7 (28.6%) | 2/7 (28.6%) | ||||||
| Tumor positive reaction* | 2/26 (7.7%) | 0/26 (0.0%) | 0/21 (0.0%) | 3/18 (17%) | 4/18 (22%) | 0/11 (0.0%) | 0/18 (0.0%) | 9/28 (32%) |
| In vitro | ||||||||
| Tumor Elispot positive T-cell response† | 7/17 (41%) | 15/17‡ (88%) | 16/17 (94%) | |||||
| Tumor-reactive antibody response§ | 4/15‖ (27%) | 5/14‖ (36%) | 3/13‖ (23%) | 5/15 (33%) | ||||
| Test performed . | Pretransplant . | Posttransplant treatment . | Follow-up . | Any time point . | ||||
|---|---|---|---|---|---|---|---|---|
| Baseline . | Day 14 . | 1 . | 4 . | 8 . | 9 mo . | Off study . | ||
| Skin DTH testing | ||||||||
| Immunotherapy positive reaction* | 26/27 (96%) | 19/19 (100%) | 18/19 (95%) | 15/16 (94%) | 27/27 (100%) | |||
| Candida positive reaction* | 6/27 (22%) | 4/23 (17%) | 7/20 (35%) | 8/17 (47%) | 6/17 (35%) | 5/10 (50%) | 6/16 (38%) | 15/28 (54%) |
| Mumps positive reaction* | 4/8 (50%) | 3/6 (50%) | 1/3 (33%) | 1/2 (50%) | 1/1 (100%) | 4/8 (50%) | ||
| Tetanus positive reaction* | 2/7 (28.6%) | 2/7 (28.6%) | ||||||
| Tumor positive reaction* | 2/26 (7.7%) | 0/26 (0.0%) | 0/21 (0.0%) | 3/18 (17%) | 4/18 (22%) | 0/11 (0.0%) | 0/18 (0.0%) | 9/28 (32%) |
| In vitro | ||||||||
| Tumor Elispot positive T-cell response† | 7/17 (41%) | 15/17‡ (88%) | 16/17 (94%) | |||||
| Tumor-reactive antibody response§ | 4/15‖ (27%) | 5/14‖ (36%) | 3/13‖ (23%) | 5/15 (33%) | ||||
A positive reaction was defined as an induration of at least 5 mm.
A positive response was defined as at least 2-fold increase over pretreatment baseline in either interferon-γ or granzyme-B production by Elispot against autologous leukemia cells.
Posttransplant results are summarized as patients with positive Elispot responses at any posttransplant time point.
A positive response was defined as development of new or increased intensity bands compared to pretreatment baseline on immunoblot against lysates of autologous leukemia cells.
Analyses conducted at posttransplant treatments 2, 3, and 7 rather than 1, 4, and 8.